Second Sight Medical Products (NASDAQ:EYES) stock just can’t stop soaring higher following approval from the U.S. Food and Drug Administration (FDA) on Friday.
Source: Who is Danny / Shutterstock.com
Here’s everything investors need to know about that approval and the continued movement for EYES stock.
- The FDA approved the company’s Argus 2s Retinal Prosthesis System.
- This is a pair of glasses and a camera that provide visions to those with retinitis pigmentosa (RP).
- The Argus 2s Retinal Prosthesis System is a redesign of a previous system.
- Update to the device includes improvements to the device.
- Among these are better ergonomics and a beefed-up processor.
- When the news was announced Friday, EYES stock got a major boost from investors.
- That movement continues today with continued interest in Second Sight Medical Products.
- As of this writing, more than 158 million shares of the stock have changed hands.
- To put that in perspective, the company’s daily average trading volume is 14 million shares.
- With all this major movement, investors are taking to social media to share their success with the stock.
- As a result, more day traders are taking an interest in the company and earning profits where they can.
- That likely explains some of the extra movement that EYES stock is seeing today.
EYES stock was up 97.7% as of Monday morning, which builds on a 304.9% rise when markets closed on Friday. The company’s stock is currently up 396.1% since the start of the year.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article.
